1. Volume 138, Issue 1, Pages 108-115 (January 2010)
Randomized Study of Peginterferon-α2a Plus Ribavirin vs Peginterferon-α2b Plus Ribavirin in Chronic Hepatitis C 
Maria Grazia Rumi, Alessio Aghemo, Gian Maria Prati, Roberta D'Ambrosio, Maria Francesca Donato, Roberta Soffredini, Ersilio Del Ninno, Antonio Russo, Massimo Colombo 
Gastroenterology 
Volume 138, Issue 1, Pages (January 2010)
DOI: /j.gastro
Copyright © 2010 AGA Institute Terms and Conditions

2. Figure 1
Flow chart of the MIST study. aNineteen patients met the week 12 stopping rule, 7 patients met the week 24 stopping rule, and 2 patients had a virologic breakthrough. Twenty of 28 patients were HCV-1, and 8 were HCV-4. bThirty-two patients met the week 12 stopping rule; 15 patients met the week 4 stopping rule; and 3 patients had a virologic breakthrough. Thirty-five of 50 patients were HCV-1, and 15 were HCV-4.
Gastroenterology  , DOI: ( /j.gastro )
Copyright © 2010 AGA Institute Terms and Conditions

3. Figure 2
Rates of virologic response for the patients with chronic hepatitis C receiving RBV combined with PegIFN-α2a or PegIFN-α2b. RVR, rapid; cEVR, complete early; EOT, end of treatment; and SVR, sustained virologic.
Gastroenterology  , DOI: ( /j.gastro )
Copyright © 2010 AGA Institute Terms and Conditions